- Home
- SMTI vs ZBIO Comparison
SMTI vs ZBIO Comparison
Compare SMTI & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTI
- ZBIO
- Stock Information
- Founded
- SMTI 1982
- ZBIO 2019
- Country
- SMTI United States
- ZBIO United States
- Employees
- SMTI N/A
- ZBIO N/A
- Industry
- SMTI Medical/Dental Instruments
- ZBIO
- Sector
- SMTI Health Care
- ZBIO
- Exchange
- SMTI Nasdaq
- ZBIO NYSE
- Market Cap
- SMTI 266.7M
- ZBIO 389.2M
- IPO Year
- SMTI N/A
- ZBIO 2024
- Fundamental
- Price
- SMTI $32.40
- ZBIO $9.29
- Analyst Decision
- SMTI Strong Buy
- ZBIO Strong Buy
- Analyst Count
- SMTI 2
- ZBIO 7
- Target Price
- SMTI $48.50
- ZBIO $32.29
- AVG Volume (30 Days)
- SMTI 20.1K
- ZBIO 160.5K
- Earning Date
- SMTI 05-14-2025
- ZBIO 05-20-2025
- Dividend Yield
- SMTI N/A
- ZBIO N/A
- EPS Growth
- SMTI N/A
- ZBIO N/A
- EPS
- SMTI N/A
- ZBIO N/A
- Revenue
- SMTI $86,672,425.00
- ZBIO $5,000,000.00
- Revenue This Year
- SMTI $23.68
- ZBIO N/A
- Revenue Next Year
- SMTI $5.80
- ZBIO N/A
- P/E Ratio
- SMTI N/A
- ZBIO N/A
- Revenue Growth
- SMTI 33.36
- ZBIO N/A
- 52 Week Low
- SMTI $25.86
- ZBIO $5.83
- 52 Week High
- SMTI $39.08
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- SMTI 56.59
- ZBIO N/A
- Support Level
- SMTI $30.54
- ZBIO N/A
- Resistance Level
- SMTI $33.14
- ZBIO N/A
- Average True Range (ATR)
- SMTI 1.07
- ZBIO 0.00
- MACD
- SMTI 0.24
- ZBIO 0.00
- Stochastic Oscillator
- SMTI 85.11
- ZBIO 0.00
About SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.